Q32 Bio (QTTB) Competitors $1.45 -0.10 (-6.45%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$1.58 +0.13 (+8.62%) As of 06/27/2025 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock QTTB vs. SRZN, JMAC, PDSB, XBIT, IZTC, IMUX, OCX, PYXS, SNTI, and STROShould you be buying Q32 Bio stock or one of its competitors? The main competitors of Q32 Bio include Surrozen (SRZN), Maxpro Capital Acquisition (JMAC), PDS Biotechnology (PDSB), XBiotech (XBIT), Invizyne Technologies (IZTC), Immunic (IMUX), OncoCyte (OCX), Pyxis Oncology (PYXS), Senti Biosciences (SNTI), and Sutro Biopharma (STRO). These companies are all part of the "pharmaceutical products" industry. Q32 Bio vs. Its Competitors Surrozen Maxpro Capital Acquisition PDS Biotechnology XBiotech Invizyne Technologies Immunic OncoCyte Pyxis Oncology Senti Biosciences Sutro Biopharma Surrozen (NASDAQ:SRZN) and Q32 Bio (NASDAQ:QTTB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings. Does the media prefer SRZN or QTTB? In the previous week, Surrozen and Surrozen both had 2 articles in the media. Surrozen's average media sentiment score of 1.31 beat Q32 Bio's score of 0.94 indicating that Surrozen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Surrozen 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Q32 Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, SRZN or QTTB? Surrozen has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500. Comparatively, Q32 Bio has a beta of -0.03, meaning that its stock price is 103% less volatile than the S&P 500. Which has stronger earnings & valuation, SRZN or QTTB? Q32 Bio has lower revenue, but higher earnings than Surrozen. Surrozen is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSurrozen$10.65M7.25-$63.56M-$24.96-0.36Q32 Bio$1.16M15.25-$47.73M-$4.94-0.29 Is SRZN or QTTB more profitable? Q32 Bio's return on equity of -447.33% beat Surrozen's return on equity.Company Net Margins Return on Equity Return on Assets SurrozenN/A -842.90% -71.32% Q32 Bio N/A -447.33%-59.77% Do analysts prefer SRZN or QTTB? Surrozen presently has a consensus price target of $38.50, suggesting a potential upside of 326.83%. Q32 Bio has a consensus price target of $12.17, suggesting a potential upside of 739.08%. Given Q32 Bio's higher probable upside, analysts clearly believe Q32 Bio is more favorable than Surrozen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Surrozen 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Q32 Bio 0 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Do insiders & institutionals hold more shares of SRZN or QTTB? 66.6% of Surrozen shares are held by institutional investors. Comparatively, 31.3% of Q32 Bio shares are held by institutional investors. 45.2% of Surrozen shares are held by insiders. Comparatively, 40.0% of Q32 Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryQ32 Bio beats Surrozen on 7 of the 13 factors compared between the two stocks. Get Q32 Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for QTTB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding QTTB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QTTB vs. The Competition Export to ExcelMetricQ32 BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$18.91M$2.84B$5.48B$8.87BDividend YieldN/A2.70%5.35%4.15%P/E Ratio-0.2921.1626.1119.66Price / Sales15.25282.55386.66105.07Price / CashN/A43.1436.4056.81Price / Book3.097.207.905.44Net Income-$47.73M-$55.15M$3.15B$249.37M7 Day Performance-6.45%0.76%3.07%3.94%1 Month Performance-20.77%6.31%6.01%5.26%1 Year Performance-91.92%-0.21%32.05%17.07% Q32 Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QTTBQ32 Bio2.779 of 5 stars$1.45-6.5%$12.17+739.1%-90.5%$18.91M$1.16M-0.2939Analyst UpgradeHigh Trading VolumeSRZNSurrozen3.1731 of 5 stars$9.54+0.6%$38.50+303.6%-9.3%$81.69M$11.64M-0.3880JMACMaxpro Capital AcquisitionN/A$6.07-12.2%N/A+3,137.3%$81.55MN/A0.002,021Gap UpPDSBPDS Biotechnology2.182 of 5 stars$1.78+1.7%$9.00+405.6%-53.2%$81.36MN/A-1.5320XBITXBiotech0.6271 of 5 stars$2.74+3.8%N/A-39.3%$80.49M$4.01M-2.54100News CoveragePositive NewsIZTCInvizyne TechnologiesN/A$12.81-2.6%N/AN/A$80.09MN/A0.0029IMUXImmunic2.6966 of 5 stars$0.82+1.9%$11.60+1,313.8%-31.4%$78.62MN/A-0.6770Analyst ForecastOCXOncoCyte2.7532 of 5 stars$2.73+3.0%$6.06+122.1%+8.7%$78.08M$3.84M-0.77120Positive NewsGap UpPYXSPyxis Oncology2.0459 of 5 stars$1.21+0.8%$9.00+643.8%-65.7%$74.96M$16.15M-1.1760SNTISenti Biosciences2.6958 of 5 stars$2.86+10.0%$8.50+197.2%-32.3%$74.59M$2.56M-0.184Gap DownSTROSutro Biopharma3.7143 of 5 stars$0.88+10.2%$6.11+594.3%-74.9%$74.38M$66.43M-0.55240Positive News Related Companies and Tools Related Companies Surrozen Competitors Maxpro Capital Acquisition Competitors PDS Biotechnology Competitors XBiotech Competitors Invizyne Technologies Competitors Immunic Competitors OncoCyte Competitors Pyxis Oncology Competitors Senti Biosciences Competitors Sutro Biopharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:QTTB) was last updated on 6/28/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump Knows Exactly What He’s Doing…With Trump in office, new money is flowing in and out of the market like never before... And some folks usi...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Q32 Bio Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Q32 Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.